Neurol. pro Praxi, 2006; 4: 185-188

Kognitivní poruchy a deprese u pacientů s cévním onemocněním mozku

MUDr. David Goldemund, PhDr. Sabina Telecká
I. neurologická klinika LF MU a FN u sv. Anny Brno

Kognitivní poruchy i deprese jsou u pacientů s cévním onemocněním mozku relativně časté a významným způsobem negativně ovlivňují jejich kvalitu života. Přesto často zůstávají nerozpoznány a neléčeny. Autoři předkládají stručný přehled týkající se výskytu, etiopatogenezy, diagnostiky a léčby těchto poruch.

Keywords: cévní onemocnění mozku, demence, vaskulární kognitivní deficit, post-stroke deprese

Published: November 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goldemund D, Telecká S. Kognitivní poruchy a deprese u pacientů s cévním onemocněním mozku. Neurol. praxi. 2006;7(4):185-188.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andersen G. Post-stroke depression and pathological crying: clinical aspects and new pharmacological approaches. Aphasiology 1997; 7 (11): 651-664. Go to original source...
    2. Andersen G, Vestergaad K, Lauritzen L. Effektive treatment od poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099-1104. Go to original source... Go to PubMed...
    3. Black S, Roman GC, Geldmacher DS et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34 (10): 2323-30. Go to original source... Go to PubMed...
    4. Clarke PJ, Marshall VW, Ryff CD, Rosenthal CJ. Well-being in Canadian seniors: findings from the Canadian Study of Health and Aging. Can J Aging 2000; 19: 139-159.
    5. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 2000; 59 (Suppl): 23-30. Go to original source... Go to PubMed...
    6. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359 (9314): 1283-90. Go to original source... Go to PubMed...
    7. Folstein MF, Folstein SE, McHigh PR., ,Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198. Go to original source... Go to PubMed...
    8. Fujikawa T, Yamawaki S, Touhouda Y. Incidence of silent cerebral infarktion in patients with major depression. Stroke 1993; 24: 1631-1634. Go to original source... Go to PubMed...
    9. Hachinski VC. Vascular dementia: a radical redefinition. Dementia 1994; 5: 130-132. Go to original source... Go to PubMed...
    10. Jorge RE, Robinson RG, Tateno A, Narushima K, Acion L, Moser D, Arndt S, Chemerinski E. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004; 55 (4): 398-405. Go to original source... Go to PubMed...
    11. Kauhanen M, Korpelainen JT, Hiltunen P, Brusin E, Mononen H, Maatta R, Nieminen P, Sotaniemi KA, Myllyla VV. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 1998; 29 (11): 2311-7. Go to PubMed...
    12. Moretti R, Torre P, Antonello RM et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003; 18 (5): 265-72. Go to original source... Go to PubMed...
    13. Murray GB, Shea V, Conn DK. Electroconvulsive therapy for poststroke depression. J Clin Psychiatry. 1986; 47 (5): 258-60.
    14. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM300). Stroke 2002; 33 (7): 1834-9. Go to original source... Go to PubMed...
    15. Pohjasvaara T, Mantyla R, Ylikoski R et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke 2000; 31 (12): 2952-7. Go to original source... Go to PubMed...
    16. Rektorova I, Megova S, Bares M, Rektor I. Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients. J Neurol Sci 2005; 15: 229-230, 157-61. Go to original source... Go to PubMed...
    17. Román GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop held at the National Institutes of Health, Bethesda, Md, April 19-21, 1991. Neurology 1993; 43: 250-260. Go to original source... Go to PubMed...
    18. Smolík P. Duševní a behaviorální poruchy. Praha: Maxdorf Jesenius 2002. 506 s.
    19. Starkstein SE, Robinson RG, Price TR. Comparison of spontaneously recovered versus nonrecovered patients with poststroke depression. J Clin Psychiatry 1989; 50 (Suppl): 18-26.
    20. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31 (8): 1829-32. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.